Global Pet Allergy Treatment Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Pet Allergy Treatment Drugs Market Research Report 2024
Allergy to cats and dogs is extremely common and occurs in up to 25% of people with allergies. Cat allergies are twice as common as dog allergies. Cat allergens are produced in large amounts, particularly by male non-neutered cats. The allergens are partially under hormonal control. Cats produce a protein known as Fel d 1, which is allergenic to human beings when it is infected with bacteria or viruses. The infected protein is contained in a pet’s urine, saliva, and skin. The dead skin of pets known as dander is regularly sloughed off and replaced by new skin cells. The dander can flake off from a pet’s fur and become airborne. It can be carried on the clothing of people who have pets such as cats and dogs and then shed in public places. Therefore, pet allergens especially that of cats and dogs, are a component of house dust even in homes where cats and dogs have never lived.
According to MRAResearch’s new survey, global Pet Allergy Treatment Drugs market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pet Allergy Treatment Drugs market research.
Key companies engaged in the Pet Allergy Treatment Drugs industry include Sunovion Pharmaceuticals Inc, Allergon AB, AbbVie(Allergan), HAL Allergy Group, Allergy Therapeutics, Teva Pharmaceutical, Viatris, GlaxoSmithKline and Stallergenes Greer, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Pet Allergy Treatment Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Pet Allergy Treatment Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Pet Allergy Treatment Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Sunovion Pharmaceuticals Inc
Allergon AB
AbbVie(Allergan)
HAL Allergy Group
Allergy Therapeutics
Teva Pharmaceutical
Viatris
GlaxoSmithKline
Stallergenes Greer
Segment by Type
Antihistamines
Decongestants
Corticosteroid
Others
Dog
Cat
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pet Allergy Treatment Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Pet Allergy Treatment Drugs market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pet Allergy Treatment Drugs market research.
Key companies engaged in the Pet Allergy Treatment Drugs industry include Sunovion Pharmaceuticals Inc, Allergon AB, AbbVie(Allergan), HAL Allergy Group, Allergy Therapeutics, Teva Pharmaceutical, Viatris, GlaxoSmithKline and Stallergenes Greer, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Pet Allergy Treatment Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Pet Allergy Treatment Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Pet Allergy Treatment Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sunovion Pharmaceuticals Inc
Allergon AB
AbbVie(Allergan)
HAL Allergy Group
Allergy Therapeutics
Teva Pharmaceutical
Viatris
GlaxoSmithKline
Stallergenes Greer
Segment by Type
Antihistamines
Decongestants
Corticosteroid
Others
Segment by Application
Dog
Cat
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pet Allergy Treatment Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source